Abstract. Our previous study demonstrated that neuroglobin (Ngb) functions as an independent predictive indicator of the prognosis of patients with glioma and promotes cancer cell growth by suppressing apoptosis. However, the understanding of the mechanisms underlying the survival-enhancing function of Ngb in glioma is limited. In the present study, KEGG PathwayFinder by gene correlation analysis was performed on the R2: Genomics Analysis and Visualization Platform, which revealed a high association between Ngb and the phosphatidylinositol 3-kinase (PI3K)/AKT pathway using glioma data (GSE4290) from the Gene Expression Omnibus database. Furthermore, western blotting experiments were performed in U251 and U87 glioma cells, and Ngb knockdown using short hairpin RNA reduced the protein levels of phosphorylated (p)-AKT, p-mammalian target of rapamycin (mTOR) and antiapoptotic factor Bcl-2, and increased the expression of the proapoptotic protein Bcl-2-associated X, in U251 cells. In addition, Ngb overexpression promoted the activation of the PI3K/AKT pathway in U87 cells. MK2206, a PI3K/AKT signaling inhibitor, reduced the expression of p-AKT and increased the levels of apoptosis-associated proteins, including cleaved poly(ADP-ribose) polymerase 1 and cleaved caspase-3/7/8, in Ngb-overexpressing U87 cells. Furthermore, MK2206 treatment reduced the proliferation and induced the apoptosis of Ngb-overexpressing U87 cells, as indicated by the results of MTT, colony formation and flow cytometry assays. In addition, insulin-like growth factor-1, a PI3K/AKT signaling activator, reversed Ngb knockdown-induced growth arrest and apoptosis in U251 cells. In conclusion, the results of the present study indicate that Ngb may facilitate a malignant phenotype of glioma cells by activating the PI3K/AKT pathway.
Introduction
Glioma, the most common form of brain malignancy, is one a major contributor to cancer-associated deaths worldwide (1) . The strategies employed for the diagnosis and treatment of glioma have improved over the past several decades (2) . However, the prognosis of patients with glioma remains poor, with a survival time of 12-18 months post-diagnosis (3) . Therefore, the identification of the exact mechanisms underlying the malignant phenotype of glioma cells is required.
Neuroglobin (Ngb), a novel tumor-associated protein, functions as an oncogene or tumor suppressor in human cancer. Previous reports have demonstrated that overexpression of Ngb enhances reactive oxygen species scavenging and reverses oxidative stress-induced cell death in neuroblastoma cells (4) (5) (6) . The expression of Ngb is upregulated under hypoxic conditions in glioblastoma cells and tumor xenografts, indicating a potential role of Ngb in cancer cell survival in hypoxic microenvironments (7, 8) . In addition to brain tumors, aberrant expression of Ngb has also been reported in other types of malignancies. For example, Ngb is reported to be overexpressed in certain non-small cell lung cancer cases, particularly in squamous cell carcinomas (9) . Notably, 17β-estradiol induces Ngb upregulation, which renders cancer cells, including MCF-7, HepG2, SK-N-BE, HeLa and DLD-1, resistant to oxidative stress (10) (11) (12) (13) . However, Ngb expression is downregulated in hepatocellular carcinoma tissues and its silencing promotes the proliferation and cell cycle progression of cancer cells (14) . Our previous study demonstrated that Ngb functions as an independent prognostic biomarker for patients with glioma and promotes the growth of cancer cells by suppressing apoptosis (15) . However, the mechanisms underlying the survival-enhancing effect of Ngb in glioma remains a challenge, therefore, the present study aimed to investigate the effect and mechanisms of Ngb in glioma.
The results of the present study demonstrated that Ngb promoted the proliferation and inhibited the apoptosis of glioma cells, which may occur through effects on the phosphatidylinositol 3-kinase (PI3K)/AKT pathway. To the best of our knowledge, the presents study is the first to indicate that Ngb may be a potential therapeutic target for glioma. and antibiotics (100 units/ml penicillin and 100 µg/ml streptomycin; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 37˚C in a humidified incubator containing 5% CO 2 . Short hairpin RNA (shRNA) targeting Ngb (5'-GUG AGU CCC UGC UCU ACA U-3') and non-targeting (NT) shRNA (5'-GCC ACA CGA UUG CUG UCU U-3') were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Vectors (1 µg) were transfected into cells at 50-70% confluency using Lipofectamine ® 2000 (Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Retroviral vector pMMP-Ngb was generated, packaged and transduced as previously described (16) . pMMP is a MFG-based vector with modifications from the myeloproliferative sarcoma virus (17) and primer binding sequence (18) Colony formation assay. Glioma cells (1x10 3 cells/well) that were transfected with the corresponding vectors were cultured in 6-well plates and maintained at 37˚C in humidified cell incubators containing 5% CO 2 for 14-21 days. U87 cells were treated with either DMSO or MK2206 (1 µM; 37˚C for 48 h) 24 h following infection with Ngb retroviruses. U251 cells were treated with either DMSO or IGF-1 (10 ng/ml; 37˚C for 48 h) 24 h following transfection with Ngb shRNA. The formed cell colonies were stained with crystal violet (0.05%; 20 min at room temperature) and counted to represent the cell proliferation of glioma cells.
Neuroglobin promotes the proliferation and suppresses the apoptosis of glioma cells by activating the PI3K/AKT pathway
Apoptosis analysis. Apoptosis in glioma cells following transfection was detected by using an Annexin V/propidium iodide (PI) kit (BD Pharmingen; BD Biosciences, San Jose, CA, USA). U87 cell were treated with either DMSO or MK2206 (1 µM; 37˚C for 48 h) 24 h post-infection with Ngb retroviruses. U251 cells were treated with DMSO or IGF-1 (10 ng/ml; 37˚C for 48 h) 24 h post-transfection with Ngb shRNA. Briefly, glioma cells were resuspended in 1X binding buffer at a concentration of 1x10 6 cells/ml. A total of 100 µl of solution (1x10 5 cells) was transferred to a 5 ml culture tube and supplemented with 5 µl of Annexin V-fluorescein isothiocyanate and 5 µl of PI. Following incubation for 15 min at 25˚C in the dark and with supplementation of 1X binding buffer (400 µl), the percentage ratio of apoptotic glioma cells was detected using FACSCalibur flow cytometer (BD Biosciences) and CellQuest Pro software (version 5.1.1; BD Biosciences).
Western blotting. U87 cells were treated with either DMSO or MK2206 (1 µM; 37˚C for 48 h) 24 h following infection with Ngb retroviruses. U251 cells were treated with either DMSO or IGF-1 (10 ng/ml; 37˚C for 48 h) 24 h post-transfection with Ngb shRNA. The transfected cells were lysed by radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, China) and phenylmethylsulfonyl fluoride (Beyotime Institute of Biotechnology) for total protein extracts, followed by quantification with a Bradford Protein assay kit (Beyotime Institute of Biotechnology). Cell lysates (40 µg/lane) were separated by 10% SDS-PAGE. After being transferred to polyvinylidene fluoride membranes (Sigma-Aldrich; Merck KGaA) and blocked with 5% non-fat milk for 1 h at room temperature, the membranes were incubated with primary antibodies against GAPDH (1:5,000; cat. no. G8140-01; US Biological, Salem, MA, USA), Ngb In_Set, number of genes in pathway that significantly correlate with Ngb expression; Total, total number of genes in pathway; Percentage, %, ratio of Ngb-associated genes in total number of genes in pathway. Statistical analysis. Data are presented as the mean ± standard deviation and were analyzed using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA). Student's t-test or one-way ANOVA followed by the post hoc Tukey's test were employed to analyze continuous variables. P<0.05 was considered to indicate a statistically significant difference.
Results

PI3K/AKT pathway is a candidate target of Ngb in glioma.
To investigate the potential mechanisms underlying the survival-enhancing effect of Ngb in glioma, KEGG PathwayFinder by gene correlation analysis using the R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl) was performed to investigate the association between Ngb and various signaling pathways in glioma. Base on the Gene Expression Omnibus (GEO) data (GSE4290) from the R2: Genomics Analysis and Visualization Platform, the results demonstrated that Ngb was strongly associated with the PI3K/AKT pathway in glioma (P<0.001; Table I ). Therefore, the PI3K/AKT pathway is a candidate target of Ngb in glioma.
Ngb regulates the PI3K/AKT pathway in glioma cells.
Subsequently, the present study investigated the activation of the PI3K/AKT pathway following modulation of Ngb levels by transfection. Ngb was silenced in U251 cells following transfection with shRNA targeting Ngb, compared with the NT shRNA group, as protein levels were reduced (P<0.05; 1 ). In addition, Ngb knockdown notably reduced the level of p-AKT (Ser473) compared with the NT shRNA group, without affecting total AKT levels, in U251 cells (P<0.05; Fig. 1 ). Furthermore, p-mTOR (Ser2448), Bcl-2 and Bax, which are downstream targets of the PI3K/ATK pathway, were also modulated by Ngb knockdown. Ngb knockdown led to reduced levels of p-mTOR (Ser2448) and Bcl-2, and increased BAX expression, in U251 cells, compared with the NT shRNA group (P<0.05; Fig. 1 ). By contrast, Ngb overexpression promoted the activation of the PI3K/AKT pathway, with increased levels of p-AKT (Ser473), p-mTOR (Ser2448) and Bcl-2, and decreased BAX expression, in U87 cells, compared with the empty vector control cells (P<0.05; Fig. 1 ). These data indicate that Ngb may promote the activation of the PI3K/AKT pathway in glioma cells.
Ngb promotes cellular malignant phenotypes of glioma by
targeting the PI3K/AKT pathway. The present study further investigated whether Ngb regulated the proliferation and apoptosis of glioma cells through targeting the PI3K/AKT pathway. Overexpression of Ngb led to increased p-AKT expression, and reduced levels of cleaved PARP and cleaved caspase-3/7/8, in U87 cells, compared with cells transfected with empty vector (P<0.05; Fig. 2A ). Functionally, Ngb overexpression promoted the proliferation and reduced the apoptosis of U87 cells, compared with cells transfected with empty vector (P<0.05; Fig. 2B-D ). An AKT inhibitor, MK2206, was employed to block the activation of PI3K/AKT in Ngb-overexpressing U87 cells. MK2206 treatment led to reduced p-AKT expression and increased levels of cleaved PARP, cleaved caspase-3, cleaved caspase-7 and cleaved caspase-8 in Ngb-overexpressing U87 cells (P<0.05; Fig. 2A) . Furthermore, MK2206 treatment reduced the proliferation and induced the apoptosis of Ngb-overexpressing U87 cells (P<0.05; Fig. 2B-D) . Ngb knockdown using shRNA led to reduced expression of p-AKT, and increased levels of cleaved PARP and cleaved caspase-3/7/8, in U251 cells, compared with cells transfected with NT shRNA (P<0.05; Fig. 3A) . In addition, Ngb knockdown reduced the proliferation and induced the apoptosis of U251 cells, compared with cells transfected with NT shRNA (P<0.05; Fig. 3B-D) . IGF-1, an activator of the PI3K/AKT pathway, increased p-AKT levels, and decreased cleaved PARP and cleaved caspase-3/7/8 expression, in Ngb-knockdown U251 cells (P<0.05; Fig. 3A) . Furthermore, IGF-1 treatment resulted in enhanced proliferation and reduced apoptosis in Ngb-knockdown U251 cells (P<0.05; Fig. 3A-D) . Therefore, these results further confirm that Ngb may promote a cellular malignant phenotype in glioma, which may occur via the PI3K/AKT pathway.
Discussion
The expression and role of Ngb in human cancer is a novel and controversial topic. Several studies have reported that Ngb may protect against oxidative stress-induced cell injury in brain cancer (4, 5, 7) . In addition, our previous study demonstrated that Ngb was overexpressed in glioma tissues compared with normal brain tissues, and its overexpression was associated with poor prognostic features and shorter overall survival (15) . Ngb has also been reported to promote the proliferation and inhibit the apoptosis of glioma cells in vitro and in vivo (15) . However, the potential mechanisms underlying the effects of Ngb in glioma are yet to be established. The present study investigated the molecular mechanisms involved in the antiapoptotic effect of Ngb in glioma cells. KEGG PathwayFinder by gene expression analysis using the R2: Genomics Analysis and Visualization Platform revealed that Ngb was associated with the PI3K/AKT pathway in glioma tissues from the GSE4290 dataset of the GEO database. Further experiments in the current study demonstrated that Ngb enhanced the activation of the PI3K/AKT pathway in glioma cells.
Aberrant activation of the PI3K/AKT pathway has been widely reported in various cancers types during progression, including glioma (20) (21) (22) . The PI3K/AKT pathway has roles in the cell proliferation, cell cycle progression and apoptosis resistance of glioma cells via its downstream targets, which include mTOR, Bcl-2, Bax, cyclin D1 and Bcl-2-like 1 (20, (23) (24) (25) (26) . mTOR was reported to have an essential role in the cell survival, proliferation and apoptosis of glioma cells (27, 28) . Bcl-2 is an antiapoptotic protein, while Bax is a proapoptotic factor. Altered Bcl-2/Bax expression was associated with altered apoptosis levels glioma cells (29) . In the present study, treatment with the AKT inhibitor MK2206 blocked the activation of the PI3K/AKT pathway, and subsequently resulted in decreased proliferation and increased apoptosis in Ngb-overexpressing U87 cells. Furthermore, IGF-1 treatment in U251 cells with Ngb knockdown enhanced the PI3K/AKT pathway activation, cell proliferation and apoptosis resistance. Therefore, Ngb may promote malignant phenotypes of glioma cells by targeting the PI3K/AKT pathway.
In conclusion, the results of the present study demonstrated that Ngb enhanced the activation of the PI3K/AKT pathway in glioma cells. Furthermore, Ngb regulated the proliferation and apoptosis of glioma cells, and these effects may occur via the PI3K/AKT pathway. Therefore, Ngb may serve as a potential target for the treatment of glioma.
